Imatinib (Gleevec®)-induced hepatotoxicity

Walid S. Ayoub, Stephen A. Geller, Tram Tran, Paul Martin, John M. Vierling, F. Fred Poordad

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Original languageEnglish
Pages (from-to)75-77
Number of pages3
JournalJournal of Clinical Gastroenterology
Volume39
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate
Pharmaceutical Preparations
Therapeutics

Keywords

  • Gleevec®
  • Hepatotoxicity
  • Imatinib

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ayoub, W. S., Geller, S. A., Tran, T., Martin, P., Vierling, J. M., & Poordad, F. F. (2005). Imatinib (Gleevec®)-induced hepatotoxicity. Journal of Clinical Gastroenterology, 39(1), 75-77.

Imatinib (Gleevec®)-induced hepatotoxicity. / Ayoub, Walid S.; Geller, Stephen A.; Tran, Tram; Martin, Paul; Vierling, John M.; Poordad, F. Fred.

In: Journal of Clinical Gastroenterology, Vol. 39, No. 1, 01.01.2005, p. 75-77.

Research output: Contribution to journalArticle

Ayoub, WS, Geller, SA, Tran, T, Martin, P, Vierling, JM & Poordad, FF 2005, 'Imatinib (Gleevec®)-induced hepatotoxicity', Journal of Clinical Gastroenterology, vol. 39, no. 1, pp. 75-77.
Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec®)-induced hepatotoxicity. Journal of Clinical Gastroenterology. 2005 Jan 1;39(1):75-77.
Ayoub, Walid S. ; Geller, Stephen A. ; Tran, Tram ; Martin, Paul ; Vierling, John M. ; Poordad, F. Fred. / Imatinib (Gleevec®)-induced hepatotoxicity. In: Journal of Clinical Gastroenterology. 2005 ; Vol. 39, No. 1. pp. 75-77.
@article{9f753029d2a545f796dc17a463c56ba0,
title = "Imatinib (Gleevec{\circledR})-induced hepatotoxicity",
abstract = "Imatinib (Gleevec{\circledR}, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.",
keywords = "Gleevec{\circledR}, Hepatotoxicity, Imatinib",
author = "Ayoub, {Walid S.} and Geller, {Stephen A.} and Tram Tran and Paul Martin and Vierling, {John M.} and Poordad, {F. Fred}",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "75--77",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Imatinib (Gleevec®)-induced hepatotoxicity

AU - Ayoub, Walid S.

AU - Geller, Stephen A.

AU - Tran, Tram

AU - Martin, Paul

AU - Vierling, John M.

AU - Poordad, F. Fred

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

AB - Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

KW - Gleevec®

KW - Hepatotoxicity

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=11144269754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144269754&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 75

EP - 77

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 1

ER -